Skip Navigation
Skip to contents

JYMS : Journal of Yeungnam Medical Science

Indexed in: ESCI, Scopus, PubMed,
PubMed Central, CAS, DOAJ, KCI
FREE article processing charge
OPEN ACCESS
SEARCH
Search

Author index

Page Path
HOME > Browse Articles > Author index
Search
Yee Soo Chae 2 Articles
Pembrolizumab-related autoimmune hemolytic anemia in a patient with metastatic lung adenocarcinoma: a case report
Dong Won Baek, Yee Soo Chae
Yeungnam Univ J Med. 2021;38(4):366-370.   Published online March 23, 2021
DOI: https://doi.org/10.12701/yujm.2021.00899
  • 4,891 View
  • 120 Download
  • 5 Crossref
AbstractAbstract PDF
Immune checkpoint inhibitors (ICIs) have become the main drugs for programmed cell death receptor-1 or ligand-1 expressing non-small cell lung cancer (NSCLC) combined with conventional chemotherapy. ICIs are generally more tolerable than cytotoxic chemotherapies in terms of toxicity, and ICI-related adverse events are mild and manageable. However, these drugs may lead to unexpected severe adverse events such as immune-related hematologic toxicities, which could be life-threatening. Here, a rare case of a pembrolizumab-related adverse event in a patient with NSCLC who showed early-onset hemolytic anemia and recovered by high-dose steroid and a series of plasma exchanges is reported.

Citations

Citations to this article as recorded by  
  • Case Report: Life-threatening pancytopenia with tislelizumab followed by cerebral infarction in a patient with lung adenocarcinoma
    Hang-Yu Gu, Jing-Wen Zhao, Yin-Shuang Wang, Zhuo-Nan Meng, Xiu-Ming Zhu, Fu-Wei Wang, Ai-Hong Zheng, Guo-Qing Wu
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • Immunotherapy-associated Autoimmune Hemolytic Anemia
    Steven R. Hwang, Antoine N. Saliba, Alexandra P. Wolanskyj-Spinner
    Hematology/Oncology Clinics of North America.2022; 36(2): 365.     CrossRef
  • Therapeutic plasma exchange in the management of immune checkpoint inhibitor‐associated immune‐related adverse effects: A review
    Oluwatoyosi A. Onwuemene, Chizoba I. Nnoruka, Christopher J. Patriquin, Laura S. Connelly‐Smith
    Transfusion.2022; 62(11): 2370.     CrossRef
  • Diagnosis and management of cold agglutinin disease associated with low-grade B-cell lymphoma in a patient receiving pembrolizumab for lung cancer
    Nabin Raj Karki, Peyton McElhone, Natasha Savage, Nagla Abdel Karim
    BMJ Case Reports.2021; 14(8): e243751.     CrossRef
  • Red Blood Cell Autoantibodies in Patients Treated with Immune Checkpoint Inhibitors
    Eungjun Yoon, Tae Yeul Kim, Sun Kyoung Mun, Duck Cho
    The Korean Journal of Blood Transfusion.2021; 32(3): 201.     CrossRef
Impressive effect of cisplatin monotherapy on a patient with heavily pretreated triple-negative breast cancer with poor performance
Dong Won Baek, Ji-Young Park, Soo Jung Lee, Yee Soo Chae
Yeungnam Univ J Med. 2020;37(3):230-235.   Published online January 22, 2020
DOI: https://doi.org/10.12701/yujm.2019.00423
  • 7,474 View
  • 153 Download
  • 7 Crossref
AbstractAbstract PDF
Systemic therapy for metastatic triple-negative breast cancer (TNBC) still remains challenging because there are no targeted agents or endocrine therapies currently available. The present case report documents the successful use of cisplatin monotherapy to manage a heavily pretreated TNBC patient showing poor response to therapy. The patient was a 51-year-old woman who had already undergone several lines of systemic chemotherapy for widespread TNBC. Although the mutation analysis performed on DNA isolated from blood cells and progressed lesion samples confirmed the tumor to be germline BRCA wild-type, cisplatin monotherapy was administered based on the increasing evidence of safety and efficacy of platinum for breast cancer. After three cycles of cisplatin treatment, the patient’s metastatic lesions dramatically improved without any major toxicity, and she completed 17 cycles with good response. This case study indicates that patients with heavily pretreated TNBC can potentially achieve a good response to cisplatin monotherapy.

Citations

Citations to this article as recorded by  
  • Zeolitic Imidazole Framework/Silica Nanocomposite for Targeted Cancer Therapeutics: Comparative Study of Chemo-Drug Cisplatin (CPt) and Green Platinum (GPt) Efficacy
    Hend Ghnaim Alotaibi, Eman Al-Abbad, Dana Almohazey, Vijaya Ravinayagam, Sultan Akhtar, Hatim Dafalla, B. Rabindran Jermy
    International Journal of Molecular Sciences.2024; 25(6): 3157.     CrossRef
  • Hypoxia: syndicating triple negative breast cancer against various therapeutic regimens
    Nityanand Srivastava, Salman Sadullah Usmani, Rajasekaran Subbarayan, Rashmi Saini, Pranav Kumar Pandey
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Inhibiting L1CAM Reverses Cisplatin Resistance of Triple Negative Breast Cancer Cells by Blocking AKT Signaling Pathway
    Lu-Yao Zhang, Zhi-Xin Shen, Lu Guo
    Cancer Investigation.2022; 40(4): 313.     CrossRef
  • Curcumin as an Enhancer of Therapeutic Efficiency of Chemotherapy Drugs in Breast Cancer
    Reyhaneh Farghadani, Rakesh Naidu
    International Journal of Molecular Sciences.2022; 23(4): 2144.     CrossRef
  • Atorvastatin improves cisplatin sensitivity through modulation of cholesteryl ester homeostasis in breast cancer cells
    Diandra Zipinotti dos Santos, Isabella dos Santos Guimaraes, Mariam F. Hakeem-Sanni, Blake J. Cochran, Kerry-Anne Rye, Thomas Grewal, Andrew J. Hoy, Leticia B. A. Rangel
    Discover Oncology.2022;[Epub]     CrossRef
  • Targeting Hypoxia Sensitizes TNBC to Cisplatin and Promotes Inhibition of Both Bulk and Cancer Stem Cells
    Andrew Sulaiman, Sarah McGarry, Jason Chambers, Emil Al-Kadi, Alexandra Phan, Li Li, Karan Mediratta, Jim Dimitroulakos, Christina Addison, Xuguang Li, Lisheng Wang
    International Journal of Molecular Sciences.2020; 21(16): 5788.     CrossRef
  • Antioxidant Supplementation in the Treatment of Neurotoxicity Induced by Platinum-Based Chemotherapeutics—A Review
    Jelena S. Katanic Stankovic, Dragica Selakovic, Vladimir Mihailovic, Gvozden Rosic
    International Journal of Molecular Sciences.2020; 21(20): 7753.     CrossRef

JYMS : Journal of Yeungnam Medical Science